Results 241 to 250 of about 339,706 (345)

Population‐Based Study Found Low Risk of Misdiagnosing Long QT Syndrome as Breath‐Holding Spells in Swedish Children

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim An electrocardiogram is commonly recommended in breath‐holding spell management, mainly to rule out long QT syndrome. This retrospective study investigated the risk of long QT syndrome being misdiagnosed as breath‐holding spells in a paediatric population in southern Sweden.
Sanna Hellström Schmidt   +3 more
wiley   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber   +4 more
wiley   +1 more source

Blood volume deficit in postural orthostatic tachycardia syndrome assessed by semiautomated carbon monoxide rebreathing [PDF]

open access: hybrid
Surat Kulapatana   +10 more
openalex   +1 more source

Consensus Guidelines for Intermittent Auscultation in United States Community Birth Settings

open access: yesBirth, EarlyView.
ABSTRACT Background Intermittent auscultation is the gold standard for fetal assessment in uncomplicated pregnancies and labors and is used universally in the community birth setting. Great variation exists in intermittent auscultation practices and language used by community birth midwives across the country. Current standards, as defined by midwifery
Silke Akerson   +5 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Typical Atrioventricular Nodal Re-entrant Tachycardia With Fasciculo-Ventricular Bypass Tract: Diagnostic and Therapeutic Challenges. [PDF]

open access: yesJACC Case Rep
Qayoom R   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy